Insomnia

Insomnia is a subjective complaint encompassing delay in onset, insufficient duration or poor quality of sleep (non-restorative sleep). Not all three symptoms need to be present for the diagnosis of insomnia to be made. Importantly, sufferers feel tired or distressed during the day.

The primary sleep disturbance is not associated with another medical disorder such as major depression and not due to the effects of a substance, for example caffeine, or a general medical condition, for example arthritis leading to pain.

Insomnia is a common condition with an overall prevalence of 27% (range 8% to 43%) among primary care attendees. The prevalence of insomnia rises from about 15% in 20-54 year olds, to 30% in the over-55 year olds. Women are 1.5 times more likely than men to have insomnia. Insomnia is associated with negative consequences in health-related quality of life, daytime well-being, cognitive skills and has significant negative economic implications.

  • Text size: A A A
  • Circadin
  • Recent news

    • Circadin® 2mg (prolonged-release melatonin) is now funded for insomnia in children and adolescents with Neurodevelopmental Disorders in New Zealand
    • Circadin® 2mg (prolonged-release melatonin) is now commercially available in Argentina
    • Neurim Pharmaceuticals Grants Exeltis Marketing Rights for Paediatric Prolonged-Release Melatonin (“PedPRM”) in Spain
  • Partners

    Partners